Superficial vein thrombosis
Also known as: Vein, Venous, Clot, Thrombosed
Methodology & AI Transparency ⓘ
Superficial vein thrombosis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Designated in federal medical registries as I82.90, Superficial vein thrombosis (also termed Vein or Venous) falls under Blood Pressure management, where D-dimer risk exclusion [Superficial vein thrombosis I82.90] establishes baseline severity and rules out diagnostic mimics.
- 2 Real-world patient consensus: Clinical coding for Superficial vein thrombosis uses ICD-10 I82.90 across Blood Pressure specialty care.
- 3 Typical cash cost range: Differential triage of Superficial vein thrombosis (I82.90) utilizes D-dimer risk exclusion [Superficial vein thrombosis I82.90].
- 4 Top reported side effects / signs: Follow-up benchmark in Superficial vein thrombosis: maintaining Urine Albumin-to-Creatinine Ratio [Superficial vein thrombosis I82.90] within < 15 mg/g (I82.90).
Ask our AI Specialists anything about Superficial vein thrombosis
What Is Superficial vein thrombosis?
Designated in federal medical registries as I82.90, Superficial vein thrombosis (also termed Vein or Venous) falls under Blood Pressure management, where D-dimer risk exclusion [Superficial vein thrombosis I82.90] establishes baseline severity and rules out diagnostic mimics.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Superficial vein thrombosis (I82.90) features elevated systemic vascular in Superficial vein thrombosis (I82.90: resistance). therapeutic stabilization in blood pressure is verified against Home Seated Blood in Superficial vein thrombosis (I82.90: Pressure).
Common Symptoms & Clinical Signs
- • Presentation of Superficial vein thrombosis (I82.90): localized extremity swelling, in Superficial vein thrombosis (I82.90: warmth, or venous)
- • Secondary Superficial vein thrombosis clinical sign: cold distal extremities in Superficial vein thrombosis (I82.90: or diminished peripheral)
- • Symptom flares in Superficial vein thrombosis correlating with Urine Albumin-to-Creatinine Ratio [Superficial vein thrombosis I82.90] deviation outside < 15 mg/g (I82.90)
- • Functional blood pressure impact requiring D-dimer risk exclusion [Superficial vein thrombosis I82.90] evaluation (I82.90)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Superficial vein thrombosis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | I82.90 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | High Blood Pressure & Vascular Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Urine Albumin-to-Creatinine Ratio [Superficial vein thrombosis I82.90] | < 15 mg/g (I82.90) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Home Seated Blood in Superficial vein thrombosis (I82.90: Pressure) | < 120/75 mmHg (I82.90) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Ankle-Brachial Index (ABI) [Superficial vein thrombosis I82.90] | 1.00 – 1.30 (I82.90) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Superficial vein thrombosis
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Acetic Acid Aceticum Acidum, VoSol • RxCUI 197305 | Anti-bacterial Agent | 92% | $1.4376 | $ 17.60 /mo |
| Lidocaine and Prilocaine Oraqix • RxCUI 197877 | Amide Local Anesthetic | 90% | $0.2164 | $ 17.26 /mo |
| Neomycin and Polymyxin B Sulfates and Hydrocortisone Otic Neomycin and Polymyxin B Sulfates and Hydrocortisone Otic Generic • RxCUI 310687 | Corticosteroid | 87% | $3.7744 | $ 161.36 /mo |
| Blood Clotter Super-Stop Bloodclotter • RxCUI 1545716 | Amide Local Anesthetic | 83% | $0.5800 | $ 31.99 /mo |
| Bacitracin Zinc and Polymyxin B Sulfate Double Antibiotic, Natureplex Antibiotic • RxCUI 308511 | Polymyxin-class Antibacterial | 89% | $2.6947 | $ 117.63 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Superficial vein thrombosis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Results of treatment with telmisartan-amlodipine in hypertensive: What a 1,461-Participant Study Found The greatest least-square mean systolic/diastolic BP reductions were observed with T80 mg plus A10 mg (-26.4/-20.1 mm Hg; P 90% with this combination. Journal of clinical hypertension (Greenwich, Conn.) • 2009-04-15 • Randomized Controlled Trial | N = 1,461 | 90/100 | PMID 19614805 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of a Single-Pill Triple Combination of Valsartan, Amlodipine, Triple combination therapy with Val/Aml/CTD demonstrated superior blood pressure reduction and a favorable safety profile in patients with essential high blood pressure inadequately controlled on Val/Aml dual therapy,... Journal of clinical hypertension (Greenwich, Conn.) • 2026-09-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 42723352 ↗ |
| Can This Approach Help? Inside the Latest Research on Adjusting Overall Survival Estimates of Macitentan in lung Arterial high blood These results from the current analyses indicate that in SERAPHIN, the standard ITT analysis was confounded by treatment switching resulting in an underestimation of the benefit of macitentan 10 mg on overall survival. Advances in therapy • 2022-09-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 35917059 ↗ |
| Can This Approach Help? Inside the Latest Research on Short-term electrophysiological effects of losartan, bisoprolol, amlodipine, and Losartan and bisoprolol have beneficial short-term ECG repolarization effects. Annals of medicine • 2009-01-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 18608135 ↗ |
| What the Latest Evidence Really Says About Effect of statins on blood pressure: Analysis on side effects released by To our knowledge, this is the first pooled analysis on large-scale data of side effects to identify the BP-lowering effect of statins. Clinical and experimental hypertension (New York, N.Y. : 1993) • 2017-01-15 • Meta-Analysis | Multi-cohort | 86/100 | PMID 28513233 ↗ |
Superficial vein thrombosis Patient Community & “People Like Me” Threads
Filter Superficial vein thrombosis community threads and patient logs by age, biological sex, dosage, and treatment duration.